1138 - Trends in Usage of Radiotherapy for Benign Conditions in a Large U.S. Health Care Claims Dataset

04:15pm - 04:20pm ET

Room 107

Presenter(s)

Brian Jeffers, MD - New York Presbyterian Hospital Columbia Campus, New York, NY

B. Jeffers¹, D. DeStephano², K. N. Kim³, D. P. Horowitz⁴, and S. K. Cheng⁵; ¹New York Presbyterian Columbia Campus, New York City, NY, ²Columbia University, New York, NY, ³Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ⁴Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY, ⁵Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY

Purpose/Objective(s):

There has been significant interest in furthering use of radiotherapy for non-CNS benign conditions. This study will examine trends of usage of radiotherapy for multiple benign conditions over a 10-year period in a large U.S. healthcare claims dataset.

Materials/Methods:

ICD-10 codes corresponding to one of 20 non-CNS benign conditions treatable with radiotherapy were generated using SNOMED-to-ICD-10-CM mappings from the OHDSI OMOP vocabulary (Athena). Patients were identified by querying Merative Marketscan’s commercial and Medicare databases for outpatient claims from 2015-2025 containing these ICD-10 codes in the primary or second diagnosis position, and patients who received radiotherapy (RT) were identified having RT procedure/planning codes linked to the benign condition. For each condition, the proportion of patients per year receiving RT was calculated for both databases. Benign conditions with a sufficient number of patients for analysis were identified, and Cochran-Armitage Trend tests were performed for each trend in proportion of RT use from 2015-2025 for each of these conditions, in both databases.

Results:

Within Marketscan’s commercial database, 10,516,219 distinct patients were identified with codes corresponding to 20 benign non-CNS conditions between 2015-2025, and 2,152,309 patients were identified within Marketscan’s Medicare database. Of these, 2496 patients in the commercial database and 958 patients in the Medicare database were identified to have received RT. Four conditions were identified with sufficient patient numbers for trend analysis: muscle calcification, Dupuytren’s disease of palm, osteoarthritis, and plantar fascial fibromatosis (concept IDs 40490403, 4308093, 80180, 134460). From 2015-2025, the proportion of use of RT for muscle calcification decreased (7.3% to 2.4% in commercial, p<0.001; 14.2% to 6.0% in Medicare, p<0.001), the proportion for Dupuytren’s increased (0.48% to 0.99%, p<0.001; 0.071% to 0.40%, p<0.001), and the proportion for osteoarthritis increased (0.0042% to 0.013%, p=0.002; 0.0051% to 0.040%, p<0.001). For plantar fascial fibromatosis, RT use increased in the commercial data (0.0073% to 0.019%, p<0.001) and decreased in the Medicare data (0.010% to 0.0%, p=0.003).

Conclusion:

This data suggests RT is playing an increasing role in the treatment of osteoarthritis/Dupuytren’s over the last 10 years, while its role in treating muscle calcifications/plantar fascial fibromatosis has lessened. However, while increasing, the absolute and relative number of patients treated with RT for osteoarthritis and Dupuytren’s remains low. This data highlights the large number of patients with benign conditions who could potentially receive RT and demonstrates the opportunity to further expand the role of RT in treatment of these conditions.